Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Perspectives on Drug Development in Early ADPKD.

Literature DB >> 35998975

Perspectives on Drug Development in Early ADPKD.

Djalila Mekahli^1,2, Hayley Womack³, Neera K Dahl⁴.

Abstract

Entities: Chemical

Keywords: ADPKD; drug development; early stages

Year: 2022 PMID： 35998975 PMCID： PMC9528262 DOI： 10.2215/CJN.05190422

Source DB: PubMed Journal: Clin J Am Soc Nephrol ISSN： 1555-9041 Impact factor: 10.614

× No keyword cloud information.

10 in total

1. Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey.

Authors: Yeoungjee Cho; Gopala Rangan; Charlotte Logeman; Hyunjin Ryu; Benedicte Sautenet; Ronald D Perrone; Annie-Claire Nadeau-Fredette; Reem A Mustafa; Htay Htay; Michel Chonchol; Tess Harris; Talia Gutman; Jonathan C Craig; Albert C M Ong; Arlene Chapman; Curie Ahn; Helen Coolican; Juliana Tze-Wah Kao; Ron T Gansevoort; Vicente Torres; York Pei; David W Johnson; Andrea K Viecelli; Armando Teixeira-Pinto; Martin Howell; Angela Ju; Karine E Manera; Allison Tong
Journal: Am J Kidney Dis Date: 2020-04-28 Impact factor: 8.860

2. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.

Authors: Emilie Cornec-Le Gall; Marie-Pierre Audrézet; Annick Rousseau; Maryvonne Hourmant; Eric Renaudineau; Christophe Charasse; Marie-Pascale Morin; Marie-Christine Moal; Jacques Dantal; Bassem Wehbe; Régine Perrichot; Thierry Frouget; Cécile Vigneau; Jérôme Potier; Philippe Jousset; Marie-Paule Guillodo; Pascale Siohan; Nazim Terki; Théophile Sawadogo; Didier Legrand; Victorio Menoyo-Calonge; Seddik Benarbia; Dominique Besnier; Hélène Longuet; Claude Férec; Yannick Le Meur
Journal: J Am Soc Nephrol Date: 2015-07-06 Impact factor: 10.121

3. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Authors: Godela M Brosnahan; Kaleab Z Abebe; Charity G Moore; Frederic F Rahbari-Oskoui; Kyongtae T Bae; Jared J Grantham; Robert W Schrier; William E Braun; Arlene B Chapman; Michael F Flessner; Peter C Harris; Marie C Hogan; Ronald D Perrone; Dana C Miskulin; Theodore I Steinman; Vicente E Torres
Journal: Am J Kidney Dis Date: 2018-01-03 Impact factor: 8.860

4. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.

Authors: Fouad T Chebib; Vicente E Torres
Journal: Am J Kidney Dis Date: 2021-03-08 Impact factor: 8.860

5. Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability.

Authors: Esther Meijer; Ron T Gansevoort
Journal: Kidney Int Date: 2020-08 Impact factor: 10.612

6. Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).

Authors: Kimberly A Smith; Aliza M Thompson; David A Baron; Steven T Broadbent; Gary H Lundstrom; Ronald D Perrone
Journal: Am J Kidney Dis Date: 2018-12-29 Impact factor: 8.860

1 in total

1. Drug Development for Cystic Kidney Diseases.

Authors: Sorin Fedeles; Ronald D Perrone
Journal: Clin J Am Soc Nephrol Date: 2022-08-23 Impact factor: 10.614

1 in total

Perspectives on Drug Development in Early ADPKD.

1. Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey.

2. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.

3. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

4. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.

5. Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability.

6. Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).

Review 7. Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016.

8. Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression.

9. Impact of liver volume on polycystic liver disease-related symptoms and quality of life.

Review 10. The wind of change in the management of autosomal dominant polycystic kidney disease in childhood.

1. Drug Development for Cystic Kidney Diseases.